An HLA-A genetic test identifies the two inherited alleles at the HLA-A locus, one of the major class I human leukocyte antigen genes. HLA-A helps immune cells recognize infected, abnormal, and transplanted cells. Testing is most often part of a broader HLA typing panel for organ or stem-cell transplantation, but it can also answer targeted questions about disease associations, medication reactions, or eligibility for certain immune therapies. Results may appear as broad antigen groups such as HLA-A2 or as high-resolution alleles such as HLA-A02:01. These are normal genetic variants, not “good” or “bad” mutations. A match at HLA-A can improve donor compatibility, but it is only one part of transplant risk. HLA-B, HLA-C, class II genes, recipient antibodies, and crossmatch findings may be equally or more important. The report’s usefulness depends on the method and resolution. A low-resolution A2 result cannot automatically substitute for exact HLA-A02:01 or HLA-A*31:01 testing.
- HLA-A testing identifies two inherited class I HLA alleles that normally remain stable for life.
- Transplant matching uses HLA-A with other HLA genes, antibody testing, and crossmatch results.
- HLA-A2 is a broad antigen group; HLA-A*02:01 is one specific allele within that group.
- A positive disease-associated allele changes probability but rarely establishes a diagnosis.
- After donor stem-cell transplantation, blood may reflect donor HLA and another specimen may be needed.
Table of Contents
- What HLA-A Is
- Why HLA-A Testing Is Ordered
- How the Test Is Done
- How to Read HLA-A Results
- HLA-A in Transplant Matching
- Disease Associations and Treatment Uses
- Limitations and Unexpected Findings
- Next Steps After an HLA-A Result
What HLA-A Is
HLA-A is a classical HLA class I gene in the major histocompatibility complex on chromosome 6. It encodes the heavy chain of an HLA-A molecule. On the cell surface, that chain pairs with beta-2 microglobulin and holds a short peptide fragment in a groove.
Most nucleated cells display HLA-A. Cytotoxic CD8 T cells inspect the peptide-HLA complex. A normal self peptide usually signals that the cell belongs to the body. A viral, tumor-associated, or otherwise altered peptide can trigger an immune response.
HLA-A is highly polymorphic. Thousands of alleles have been named, and their frequencies differ among populations. This variation changes the shape of the peptide-binding groove, which influences which peptides can be presented.
Each person normally inherits one HLA-A allele from each biological parent. A report may therefore show two different alleles, such as HLA-A02:01 and HLA-A24:02, or the same allele twice. Having the same allele on both chromosomes is called homozygosity.
HLA-A belongs to a linked HLA haplotype that also contains HLA-B, HLA-C, and class II genes. Haplotypes are often inherited as blocks, but the clinical report usually lists each locus separately.
HLA-A variation is normal. The term “variant” here does not imply a rare pathogenic mutation. Most HLA-A alleles are common, healthy forms shaped by human evolution and infectious pressure.
The immune system can form antibodies against an HLA-A allele that it recognizes as foreign after pregnancy, transfusion, or transplant. Those antibodies are separate from the inherited genotype. A person can have HLA-A*02:01 and also make antibodies against a different HLA-A antigen.
Why HLA-A Testing Is Ordered
HLA-A is rarely tested in isolation for transplantation. It is usually one component of a comprehensive panel that answers a specific clinical question.
Organ transplantation
Kidney and other solid-organ programs type donor and recipient HLA-A. The comparison contributes to the mismatch count and allows the laboratory to determine whether recipient antibodies target donor HLA-A.
A recipient with anti-HLA-A2 antibody may be incompatible with a donor carrying an A2-group allele. Higher-resolution donor typing may be needed to decide whether the antibody is truly donor-specific.
Hematopoietic stem-cell transplantation
High-resolution HLA-A matching is a core part of unrelated donor selection. An 8/8 match usually includes both alleles at HLA-A, HLA-B, HLA-C, and HLA-DRB1. A mismatch at HLA-A can increase graft-versus-host disease or mortality risk, although the effect depends on the exact mismatch and transplant platform.
Family members may be tested to identify an HLA-identical sibling or a haploidentical donor. A parent and child usually share one HLA haplotype.
Disease association
Certain HLA-A alleles are associated with altered risk of autoimmune, infectious, or inflammatory diseases. Associations vary by ancestry and often reflect interaction with other HLA genes. HLA-A testing alone is rarely the standard diagnostic test for these conditions.
Medication hypersensitivity
HLA-A*31:01 is associated with carbamazepine hypersensitivity, including maculopapular eruption, drug reaction with eosinophilia and systemic symptoms, and severe blistering reactions in some populations. This is a targeted pharmacogenetic use and requires exact allele identification.
Cancer immunotherapy and cellular therapy
Some T-cell receptor therapies recognize a tumor peptide only when it is presented by a specific HLA-A allele. Eligibility may require a result such as HLA-A*02:01. Broad HLA-A2 serology may be insufficient if the therapy specifies an allele.
Platelet support and research
HLA-A typing can help select compatible platelets for patients with HLA antibodies and transfusion refractoriness. It is also widely used in vaccine, infection, tumor-immunity, and population-genetics research.
The ordering indication should be stated clearly. The laboratory may use different methods and reporting rules for transplant matching, a single drug-risk allele, or cell-therapy eligibility.
How the Test Is Done
Testing usually uses blood or a cheek swab. No fasting is required. DNA is extracted and analyzed with an HLA-specific method.
Older serologic typing exposes lymphocytes to antibodies and identifies broad antigens such as A1, A2, A3, A11, A24, or A26. Serology is rapid but cannot distinguish many molecular alleles.
Modern DNA methods include:
- Sequence-specific primers, which amplify selected HLA-A variants
- Sequence-specific oligonucleotide probes, which detect defined sequence motifs
- Sanger sequencing, which reads key coding exons
- Next-generation sequencing, which reads multiple HLA genes and reduces ambiguity
- Long-read sequencing, which can phase long stretches of one allele
A targeted test for HLA-A*31:01 may use a small allele-specific assay. A transplant panel generally uses broader typing. The result should state the method and achieved resolution.
Low-resolution typing identifies an allele group such as HLA-A02. High-resolution typing identifies the protein-level allele, such as HLA-A02:01. Full allelic resolution may add synonymous and noncoding fields.
The laboratory must distinguish HLA-A from closely related HLA class I sequences. Rare alleles, gene conversions, null alleles, and incomplete coverage can create ambiguity. Confirmatory testing may use an independent method or a new sample.
For deceased-organ donation, rapid typing may be performed under strict time pressure. A later confirmatory result can add resolution. For stem-cell donation, a registry typing result is normally confirmed from a new sample before collection.
Specimen choice is important after allogeneic stem-cell transplant. Blood and many cheek swabs can contain donor-derived cells. If the recipient’s inherited HLA-A is needed for drug risk or disease testing, the laboratory may use a pretransplant sample, hair follicles, or cultured skin cells.
How to Read HLA-A Results
A high-resolution result may look like:
- HLA-A*02:01
- HLA-A*24:02
The gene name comes first. The asterisk separates the gene from the allele. The first field identifies an allele group, and the second field identifies the protein sequence. Additional fields can distinguish silent coding or noncoding differences.
A report of HLA-A2 is broader than HLA-A02:01. The A2 serologic group includes many alleles, such as HLA-A02:01, *02:02, *02:03, and others. They can differ in population distribution, peptide binding, antibody reactivity, and therapy eligibility.
Result patterns include:
Heterozygous result
Two different alleles are detected. This is common and may broaden the range of peptides the person can present.
Homozygous result
The same allele is detected on both inherited copies. The report may list it twice or state homozygosity. Homozygosity can reduce the number of distinct HLA-A targets available for peptide presentation, but it is not a disease diagnosis.
Positive targeted allele
A targeted assay may report “HLA-A*31:01 detected.” This means at least one copy is present unless the report specifies two. The clinical meaning depends on the indication; for carbamazepine, it signals increased hypersensitivity risk.
Negative targeted allele
“HLA-A*31:01 not detected” means the assay did not find that allele. It does not mean the HLA-A gene is absent. The person still has two other HLA-A alleles.
Ambiguous typing
The laboratory may list several possible alleles because the tested regions are identical among them. If the ambiguity affects donor matching or treatment eligibility, additional sequencing can resolve it.
Null or low-expression allele
A suffix may show unusual expression. “N” indicates a null allele, while “L” indicates low expression. These findings can change transplant matching or antibody interpretation and should be reviewed by a histocompatibility specialist.
Do not interpret an HLA-A allele using a generic DNA mutation framework. A common HLA allele is not labeled pathogenic or benign. Its meaning is relational: it may match a donor, serve as an antibody target, alter a drug reaction risk, or present a particular therapeutic peptide.
HLA-A in Transplant Matching
HLA-A contributes to donor-recipient compatibility, but its importance differs among transplant types.
In kidney transplantation, HLA-A is part of the traditional HLA-A, B, and DR mismatch count. A donor and recipient can match at zero, one, or both HLA-A alleles or antigens. Closer matching can reduce immune stimulation, but waiting for an HLA-A match may not be worth prolonged dialysis or loss of a strong living-donor opportunity.
Recipient antibody status can matter more than the match count. If a recipient has a strong antibody against the donor’s HLA-A, that is a donor-specific antibody. It can produce a positive crossmatch and increase antibody-mediated rejection risk. The transplant team interprets the DSA result with antibody strength, history, and cell-based testing.
In hematopoietic transplantation, high-resolution HLA-A matching is usually part of the core unrelated-donor match. A mismatch changes both graft-versus-host and host-versus-graft recognition. The exact amino-acid difference, donor age, disease, graft source, and GVHD-prevention regimen influence its effect.
A numerical HLA match result should state which loci were counted. A 10/10 match includes HLA-A at both alleles but does not mean every HLA gene is identical.
HLA-A antibodies may recognize broad antigen groups, public epitopes shared across several alleles, or allele-specific structures. The laboratory may need high-resolution donor typing to determine whether an apparent antibody specificity truly matches the donor.
HLA-A expression can vary among alleles and tissues. Inflammation may increase class I expression on graft endothelium. Research suggests that expression and structural mismatch can refine risk, but routine decisions still rely mainly on validated typing, antibody specificity, crossmatch, and transplant protocol.
A perfect HLA-A match does not guarantee graft survival. HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA-DP, non-HLA antigens, immunosuppression, adherence, organ quality, and infections all contribute.
Disease Associations and Treatment Uses
HLA-A alleles influence antigen presentation and can be associated with disease susceptibility, protection, or clinical course. These are statistical relationships, not deterministic results.
Examples reported in research include associations with viral control, autoimmune conditions, cancers, and adverse drug reactions. The specific allele, ancestry, linked haplotype, and comparison group matter. An association attributed to HLA-A may partly reflect a nearby linked gene.
HLA-A*31:01 has one of the clearest clinical uses. Before carbamazepine, a positive result can guide selection of an alternative medication because the allele raises the risk of several hypersensitivity phenotypes. This targeted test is covered separately from general HLA-A tissue typing.
HLA-A02:01 is relevant to some peptide vaccines, diagnostic immune assays, and engineered T-cell receptor therapies. A treatment may require tumor expression of a particular antigen plus the exact HLA allele needed to present it. Being HLA-A02:01-positive does not mean a person has cancer or will respond to the therapy.
In infectious disease, HLA-A alleles can shape which viral peptides are recognized and how quickly viruses escape immune pressure. These findings are important in research but rarely justify stand-alone clinical testing.
Disease-risk associations should be interpreted using absolute risk. Even a strong relative association may translate into a low chance of disease if the condition is rare. Conversely, absence of an allele does not exclude a common disease with many genetic and environmental causes.
Broad HLA-A testing is not a general immune-health screen. It cannot measure vaccine response, infection susceptibility overall, or immune competence. Immunoglobulin levels, blood counts, functional assays, and clinical history answer those questions more directly.
Limitations and Unexpected Findings
The largest limitation is using a result at the wrong resolution. An A2 antigen result may be adequate for an older mismatch count but not for a drug label, research protocol, or allele-restricted therapy.
Other limitations include:
- Allele ambiguity when only selected exons are tested
- Rare variants that primer- or probe-based methods miss
- Sample labeling or identity errors
- Mixed DNA after stem-cell transplant
- Incomplete detection of deletions, duplications, or novel alleles
- Changes in allele nomenclature as databases expand
- Imputed HLA results that are less certain than direct typing
HLA imputation estimates alleles from nearby genetic markers. It is useful in research but accuracy varies by ancestry and reference panel. A clinically actionable result should usually be confirmed by direct typing.
Direct-to-consumer raw data often contains only a few markers near HLA-A. It generally cannot reconstruct a high-resolution allele reliably, especially in underrepresented populations.
A mismatch between serology and DNA can reflect a null allele, low expression, cross-reactive antibody group, or older naming convention. The laboratory should reconcile the methods rather than assuming one result is wrong.
HLA-A typing can incidentally reveal unexpected biological relationships. Before family donor testing, programs should explain that inherited haplotypes may raise questions about parentage or sibling relationships. Sample error must be ruled out first.
Cancer cells can lose an HLA allele as an immune-evasion mechanism. Tumor sequencing may therefore show loss of HLA-A even though normal cells retain the inherited allele. Tumor-only data should not replace germline typing for transplant or medication decisions.
After an allogeneic stem-cell transplant, a blood HLA-A result may correctly identify the donor immune system but not the recipient’s original genotype. The correct answer depends on whether the question concerns current donor-derived blood cells or inherited recipient tissue.
Next Steps After an HLA-A Result
Ask the ordering clinician or laboratory what question the test answered. Useful questions include:
- Was this broad antigen typing or high-resolution allele typing?
- Which two HLA-A alleles were identified?
- Is any ambiguity clinically important?
- Was the specimen affected by a prior stem-cell transplant?
- For transplantation, how does HLA-A compare with the other HLA loci?
- Does the recipient have antibodies against either donor HLA-A allele?
- For a drug or therapy, does the assay confirm the exact required allele?
- Does the result need independent confirmation?
For transplant matching, review HLA-A as part of the complete donor profile. Do not accept or reject a donor from one locus alone. Ask for the antibody and crossmatch interpretation, donor quality, and alternative donor options.
For a targeted medication result, place the exact allele in the permanent medication record. HLA genotype does not normally need repeating. If the report only says A31 or A2, confirm that the method achieved the allele resolution required by the prescribing guideline.
For cell-therapy eligibility, confirm both the HLA allele and all other eligibility criteria. A positive HLA-A*02 result may require subtype confirmation, tumor antigen testing, disease stage, and organ-function assessment.
For disease-risk findings, avoid screening relatives or changing care without a defined clinical benefit. Focus on symptoms and validated diagnostic tests. A common HLA-A allele usually provides only one small part of risk.
Keep the full report, including specimen type, method, resolution, allele names, and date. When care transfers, send the original result rather than a portal summary.
An HLA-A result becomes useful only when its precision matches the clinical decision. Broad tissue type, high-resolution transplant allele, drug-risk marker, and therapy restriction are related uses, but they are not interchangeable.
Population frequency can help explain how easy or difficult it may be to find a matched donor, but it should not be used to assign identity or ancestry to one person. The same HLA-A allele can occur in many populations, and a person’s complete haplotype may be uncommon even when each individual allele is familiar. Donor registries therefore benefit from broad participation across communities rather than relying on racial labels as a substitute for typing.
Family testing also needs careful interpretation. A full sibling has a 25% chance of inheriting the same two parental HLA haplotypes, a 50% chance of sharing one, and a 25% chance of sharing neither, assuming ordinary inheritance. These probabilities describe haplotypes, not isolated HLA-A alleles. Two siblings can match at HLA-A yet differ substantially at HLA-B, HLA-C, or class II loci.
For allele-restricted immune therapy, the laboratory should confirm the exact nomenclature requested by the protocol. A therapy labeled for HLA-A*02:01 may not accept every HLA-A2 subtype, and some assays designed for transplant screening report only a broad A2 group. Eligibility also depends on disease, tumor antigen expression, prior treatment, organ function, and trial or product criteria. The HLA result opens one gate; it does not establish benefit.
When an HLA-A result appears inconsistent with an older report, first compare resolution and nomenclature. “A2” and “A*02:01” can both be correct at different levels. True discrepancies should prompt review of specimen identity, transfusion or transplant history, assay coverage, and whether one test examined tumor rather than germline DNA.
HLA-A can also become relevant when platelet transfusions fail to produce the expected count rise. If immune refractoriness is confirmed, a blood bank may select HLA-matched or antibody-compatible platelets using HLA-A and HLA-B information. Fever, infection, bleeding, splenic enlargement, and certain medicines can also reduce platelet increments, so typing is only one part of that evaluation.
For any clinical use, avoid relying on a patient-generated interpretation from allele-frequency websites. Frequency does not establish disease, compatibility, or therapy eligibility. The laboratory report and the indication-specific guideline provide the clinically meaningful interpretation.
References
- Topography of the HLA-A protein enforces shared and convergent immunodominant B cell and antibody alloresponses in transplant recipients 2025
- HLA Genetics for the Human Diseases 2024 (Review)
- The most frequent HLA alleles around the world: A fundamental synopsis 2024 (Review)
- HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation 2024 (Review)
- A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing 2024 (Review)
- HLA allele-specific expression: Methods, disease associations, and future perspectives 2022 (Review)
Disclaimer
This article provides general information and cannot interpret an individual HLA-A result for transplant, disease, medication, or therapy eligibility. The ordering clinician and, when relevant, a histocompatibility laboratory should review the exact allele, method, resolution, specimen, and clinical purpose. Do not make donor or medication decisions from a broad or unconfirmed result.
